A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Inclusion Criteria14

• Age:
• Males and females ≥18 years of age at the time of consent
• Type of Participant and Disease Characteristics:
• Participant must have documented diagnosis of MM per IMWG diagnostic criteria
• ECOG performance status of 0 or 1.
• Adequate organ and bone marrow function.
• For NDMM participants:
• Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prior anti- myeloma therapy (no more than 2 cycles of induction therapy before enrollment are acceptable)
• For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and a maximum of 6 cycles of induction therapy completed prior to screening
• Classified as high-risk MM
• For Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants:
• Have received and failed 1 or 2 lines of anti-myeloma therapy
• Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as part of their previous therapy
• Have documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria within 1 year of starting treatment, or on or within 6 months of completing treatment of the subject's last line of anti-myeloma therapy, or have confirmed progressive disease within 6 months prior to screening and who are subsequently determined to be refractory or non-responsive to their most recent anti-myeloma treatment regimen